



Welcome



TB Alliance | Drug development pipeline*

DISCOVERY

EARLY DEVELOPMENT

LATE DEVELOPMENT

LEAD IDENTIFICATION

DnaN
X-Chem

Host-Directed Therapy
DoD
ITHEMYC

PEPCK
UIC

PknB
X-Chem

PknB Protac
DoD

PptT
Evotec
Texas A&M
UNC
WCM

Whole Cell Hit-to-Lead Program
GSK

LEAD OPTIMIZATION

Anti-TB Natural Products
Evotec

ClpC1
Harvard
UIC

ClpP1P2 Programs
GHDDI
Harvard
UIC

Intracellular Active Series
Evotec

Intracellular Active Series
GSK

MmpL3 Inhibitors
Lgenia
GHDDI

RNA Polymerase Inhibitors
Lgenia
UIC

PRECLINICAL DEVELOPMENT

Long-Acting Injectables (LAIs)
Pretomanid
TBAJ-876
TBAJ-587
Q-203

Preclinical TB Regimen Development
ERA4TB
JHU
TBDA
UCSF

PAN-TB Collaboration
BMGF



Scan here for the online portfolio

PHASE 1

PHASE 2

TBAJ-587 /Diarylquinoline
ERA4TB
UNITE4TB

BPamZ /SEM
UoSA
NCOOS

TBAJ-876 /Diarylquinoline

Q-203
ERA4TB
NCATS
Qurient

Sutezolid / Oxazolidinone
PAN-HM | Aurum
PAN-TB | Gates MRI ,
Janssen, Otsuka
RAD-TB | ACTG

TBA-7371 / DprE1 Inhibitor
FNDR
Gates MRI

TBI-223 / Oxazolidinone
IMM
RAD-TB | ACTG

PHASE 3

Completed

BPaL
bedaquiline + pretomanid + linezolid
Viatrix
NixTB

BPaL
bedaquiline + pretomanid + linezolid
Viatrix
ZeNix

BPamZ **SIMPLICITB**
bedaquiline + pretomanid + moxifloxacin + pyrazinamide
PanACEA
Radboud
Viatrix

TB Practecal
Innovating MDR-TB Treatment

BPaL/M
bedaquiline + pretomanid + linezolid + moxifloxacin
MSF Amsterdam

MARKETED PRODUCTS

OPTIMIZED PEDIATRIC FORMULATIONS with Macleods
Ethambutol
Isoniazid
Pyrazinamide
Rifampicin / Isoniazid
Rifampicin / Isoniazid / Pyrazinamide

PEDIATRIC FORMULATION DEVELOPMENT
Pretomanid
Viatrix



PRETOMANID FOR USE IN BPaL
Pretomanid for use in BPaL and BPaL/M Regimens
Hongqi
Lupin
Macleods
Remington
Viatrix

*As of March 2026. This document is updated on a quarterly basis.





Transforming Active TB treatments


A PROJECTED VISION FOR SHORTER, SIMPLER TB CARE



The future of TB therapy




ONE DAY
to treat latent
TB infections



ONE MONTH
to treat active
TB infections





Achieving 1x1

SUSTAINABLE PIPELINE



of highly effective
and safe novel
therapeutics

LEVERAGING ADVANCES



in a variety of
technological
advances

ACCESS FOR ALL



reaching all
who need them